It is currently 30 Sep 2020 00:03

All times are UTC + 5:30 hours [ DST ]




Post new topic Reply to topic  [ 1 post ] 
Author Message
PostPosted: 24 Jul 2020 02:58 
Offline
User avatar

Joined: 24 Mar 2013 02:28
Posts: 751
ANNALS OF INTERNAL MEDICINE
Original Research16 Jul 2020
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.
A Randomized Trial

Background:

No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).

Objective:

To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.

Design:

Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020.

Setting:

Internet-based trial across the United States and Canada (40 states and 3 provinces).

Participants:

Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.

Intervention:

Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo.

Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.

Results:

Of 491 patients randomly assigned to a group, 423 contributed primary end point data.
Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting.

Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups .
At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21).

Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P < 0.001).

With placebo, 10 hospitalizations occurred (2 non–COVID-19–related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29).

Limitations:

Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages.

Conclusion:

Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.


Top
 Profile Send private message  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC + 5:30 hours [ DST ]


Who is online

Users browsing this forum: No registered users and 1 guest


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Jump to:  
cron